
vTv Therapeutics (VTVT) Stock Forecast & Price Target
vTv Therapeutics (VTVT) Analyst Ratings
Bulls say
vTv Therapeutics is well positioned in the diabetes treatment market and has a strong pipeline with potential for growth. The positive results from previous studies and the expected results from the ongoing Phase 3 trial suggest promising revenue potential in the future. Additionally, partnerships and collaborations with other companies highlight the company's expertise and potential for further advancements in the field of chronic disease treatment. On a fundamental level, vTv Therapeutics has the potential for success and is likely to see long-term growth in the market.
Bears say
vTv Therapeutics is a late-stage biopharmaceutical company with a focus on developing oral, small-molecule drug candidates for the treatment of chronic diseases, such as diabetes. While the company's pipeline includes multiple drug candidates, the most promising one is cadisegliatin (TTP399), which has shown positive results in clinical trials for the treatment of type 2 diabetes. However, there are still concerns regarding its efficacy and safety profile in type 1 diabetes and the potential regulatory risks involved. The company's current financials and partnerships also present risks to its success. Therefore, the negative outlook on vTv Therapeutics' stock is primarily driven by these fundamental factors.
This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
vTv Therapeutics (VTVT) Analyst Forecast & Price Prediction
Start investing in vTv Therapeutics (VTVT)
Order type
Buy in
Order amount
Est. shares
0 shares